{
    "nct_id": "NCT03040726",
    "official_title": "Fixed-Dose Netupitant and Palonosetron for Chronic Nausea and Vomiting in Cancer Patients",
    "inclusion_criteria": "* Diagnosis of cancer\n* Chronic nausea over the past 4 weeks\n* Average nausea numeric rating scale >= 4/10 over the past 5 days at screening\n* Outpatient at MD Anderson Cancer Center\n* Karnofsky performance status >= 50%\n* Age 18 or older\n* Able to complete study assessments, including keeping a daily diary\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Delirium (i.e. Memorial Delirium Rating Scale > 13)\n* Clinical evidence of bowel obstruction at the time of study enrollment\n* Expected to use other 5HT3 antagonists or NK1 antagonists for prophylaxis during the study\n* Continuation of over-the-counter therapies for nausea and/or vomiting during the study\n* On cytotoxic chemotherapy in the high/moderate/low emetogenic risk categories or oral antineoplastic agents in the high or moderate emetogenic risk categories according to the latest National Comprehensive Cancer Network (NCCN) guideline within 2 weeks of study enrollment\n* On scheduled potent CYP3A4 inducers at the time of study enrollment (avasimibe, carbamazepine, phenytoin, rifampin, efavirenz, nevirapine, barbiturates, systemic glucocorticoids, modafinil, oxcarbazine, phenobarbital, pioglitazone, rifabutin, St. John's wort, troglitazone)\n* On scheduled CYP3A4 substrates with narrow safety range at the time of study enrollment (alfentanil, cyclosporine, dihydroergotamine, ergotamine, pimozide, quinidine, sirolimus, tacrolimus)\n* On scheduled strong or moderate CYP3A4 inhibitors (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole; amprenavir, aprepitant, atazanavir, ciprofloxacin, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil) within one week of study enrollment\n* Unwilling to provide informed consent\n* Severe renal impairment (calculated creatinine clearance =< 29 cc/min)\n\n  * Calculated creatinine clearance can be done within 14 days of study enrollment\n* Severe liver impairment (Child-Pugh score > 9)\n\n  * Total (T.) bilirubin, albumin, prothrombin time, and serum creatinine tests can be done within 14 days of study enrollment (only if not performed in the last 14 days)\n* Females who are pregnant, lactating, or intend to become pregnant during the participation of the study; childbearing age women who are not on birth control; positive pregnancy test for women of childbearing potential, as defined by intact uterus and ovaries, and no history of menses within the last 12 months; pregnancy test to be performed on the day of enrollment; in cases of women with elevated beta-human chorionic gonadotropin (b-HCG), these candidates will be eligible to participate so long as the level of b-HCG is not consistent with pregnancy and the non-pregnant status is confirmed by a gynecologic examination",
    "miscellaneous_criteria": ""
}